TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
The Revenues of TORRENT PHARMACEUTICALS have increased by 11.51% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 15.39 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹10,728 Cr | ₹9,620 Cr | ₹8,508 Cr | ₹8,005 Cr | ₹7,939 Cr |
Expenses | ₹7,364 Cr | ₹6,796 Cr | ₹6,077 Cr | ₹5,524 Cr | ₹5,769 Cr |
Operating Profit (Excl OI) | ₹3,364 Cr | ₹2,824 Cr | ₹2,431 Cr | ₹2,480 Cr | ₹2,170 Cr |
Other Income | ₹62 Cr | ₹63 Cr | ₹197 Cr | ₹57 Cr | ₹121 Cr |
Interest | ₹354 Cr | ₹333 Cr | ₹255 Cr | ₹353 Cr | ₹451 Cr |
Depreciation | ₹808 Cr | ₹707 Cr | ₹662 Cr | ₹658 Cr | ₹654 Cr |
Profit Before Tax | ₹2,352 Cr | ₹1,847 Cr | ₹1,226 Cr | ₹1,526 Cr | ₹1,187 Cr |
Profit After Tax | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr |
Consolidated Net Profit | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr |
Earnings Per Share (Rs) | ₹56.47 | ₹48.94 | ₹36.79 | ₹45.92 | ₹73.97 |
PAT Margin (%) | 11.34 | 9.92 | 7.63 | 5.11 | 8.41 |
ROE(%) | 26.46 | 25.38 | 20.50 | 13.18 | 23.49 |
ROCE(%) | 27.32 | 24.28 | 20.32 | 14.35 | 17.62 |
Total Debt/Equity(x) | 0.40 | 0.57 | 0.85 | 0.68 | 0.83 |
Key Financials |
||
Market Cap | : | ₹ 112,117.0 Cr |
Revenue (TTM) | : | ₹ 11,516.0 Cr |
Net Profit(TTM) | : | ₹ 1,911.0 Cr |
EPS (TTM) | : | ₹ 56.5 |
P/E (TTM) | : | 58.7 |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | -1.1% | 1.6% | 13.7% |
SUN PHARMACEUTICAL INDUSTRIES | -0.4% | -0.9% | 4.8% |
DIVIS LABORATORIES | -0.7% | 1.6% | 50.2% |
CIPLA | -1.7% | -1.1% | -2.3% |
DR REDDYS LABORATORIES | -4.3% | -8% | -4.4% |
MANKIND PHARMA | 6.8% | 8% | 20.9% |
ZYDUS LIFESCIENCES | -1.9% | 0.1% | -16.5% |
LUPIN | -4.3% | -6.4% | 4.6% |
AUROBINDO PHARMA | -5.1% | -2.7% | -15.3% |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 11.51 % |
5 Yr CAGR | 7.82 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹10,728 Cr | 11.51 | |
Mar2024 | ₹9,620 Cr | 13.07 | |
Mar2023 | ₹8,508 Cr | 6.29 | |
Mar2022 | ₹8,005 Cr | 0.82 | |
Mar2021 | ₹7,939 Cr | - |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 19.11 % |
5 Yr CAGR | 11.58 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹3,364 Cr | 19.11 | |
Mar2024 | ₹2,824 Cr | 16.15 | |
Mar2023 | ₹2,431 Cr | -1.97 | |
Mar2022 | ₹2,480 Cr | 14.27 | |
Mar2021 | ₹2,170 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 6.81 % |
5 Yr CAGR | 3.48 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 31.35% | 6.81 | |
Mar2024 | 29.35% | 2.69 | |
Mar2023 | 28.58% | -7.75 | |
Mar2022 | 30.98% | 13.31 | |
Mar2021 | 27.34% | - |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 33.02 % |
5 Yr CAGR | 12.76 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹1,656 Cr | 33.02 | |
Mar2024 | ₹1,245 Cr | 60.22 | |
Mar2023 | ₹777 Cr | -37.92 | |
Mar2022 | ₹1,252 Cr | 22.17 | |
Mar2021 | ₹1,025 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 14.31 % |
5 Yr CAGR | 7.76 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 11.34 % | 14.31 | |
Mar2024 | 9.92 % | 30.01 | |
Mar2023 | 7.63 % | 49.32 | |
Mar2022 | 5.11 % | -39.24 | |
Mar2021 | 8.41 % | - |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 15.39 % |
5 Yr CAGR | -6.53 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹56 | 15.39 | |
Mar2024 | ₹49 | 33.03 | |
Mar2023 | ₹37 | -19.88 | |
Mar2022 | ₹46 | -37.92 | |
Mar2021 | ₹74 | - |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 12.52 % |
5 Yr CAGR | 11.59 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 27.32% | 12.52 | |
Mar2024 | 24.28% | 19.49 | |
Mar2023 | 20.32% | 41.60 | |
Mar2022 | 14.35% | -18.56 | |
Mar2021 | 17.62% | - |
TORRENT PHARMACEUTICALS Share Price vs Sensex
Current Share Price | : | ₹3,313.2 |
Current MarketCap | : | ₹ 112,117.0 Cr |
Updated EOD on | : | Jul 11,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TORRENT PHARMACEUTICALS | -1.1% |
1.6% |
13.7% |
SENSEX | -1.1% |
-0% |
3.2% |
TORRENT PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
BSE MIDCAP | -1.1% | -0.5% | -2.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 EQUAL WEIGHT | -0.7% | -0.3% | -0.3% |
NIFTY PHARMA | -0.7% | 0.8% | 9.4% |
NIFTY ALPHA QUALITY LOW-VOLATILITY 30 | -0.9% | -0.5% | -6.7% |
NIFTY NEXT 50 | -0.9% | -1.2% | -7.5% |
NIFTY100 LOW VOLATILITY 30 | -1% | 0.8% | 3.9% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 11.51% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 15.39 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs